Physician profile
Edwin Gunn
NPI 1982066643
$3,714.03
in general payments reported to CMS, 2019-2025
15 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $45.13 · 2024: $2,902 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $1,154 · Travel and Lodging: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $1,153.86 |
| Travel and Lodging | $1,060.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,641.63 | 2024 | |
| Glaxosmithkline, LLC. | $296.64 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $136.55 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.26 | 2023-2025 | Ofev, Jascayd |
| Insmed, INC. | $131.47 | 2024-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $99.34 | 2023-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $92.43 | 2024-2025 | Dupixent |
| Genzyme Corporation | $30.14 | 2024 | |
| Amgen INC. | $30.09 | 2024-2025 | Tezspire |
| Abbvie INC. | $26.03 | 2025 | |
| Grifols USA, LLC | $22.54 | 2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $20.16 | 2025 | Acthar |
| Philips North America LLC | $19.46 | 2024 | (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $17.23 | 2024 | Opsumit |
| La Jolla Pharmaceutical Company | $15.06 | 2025 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Gunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.